Metabolic profiling of HepG2 cells incubated with S(-) and R(+) enantiomers of anti-coagulating drug warfarin

Metabolomics

Volumn 7, Issue 3, 2011, Pages 353-362

  Bai, Jing ^a   Wang, Ming Xuan ^a   Chowbay, Balram ^b   Ching, Chi Bun ^a   Chen, Wei Ning ^a  

^a Nanyang Technological University   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Chiral drugs; Metabolic profiling; Warfarin

Indexed keywords

ARACHIDONIC ACID; GLUCURONIC ACID; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLYCINE; LACTIC ACID; PYROGLUTAMIC ACID; SERINE; THREONINE; VALINE; VITAMIN K GROUP; WARFARIN;

AMINO ACID COMPOSITION; ARTICLE; BIOLOGICAL ACTIVITY; CELL INTERACTION; CELL LEVEL; CELL METABOLISM; CELL STRAIN HEPG2; CHEMOMETRIC ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENANTIOMER; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; LIVER CELL; MASS FRAGMENTOGRAPHY; METABOLITE; PROTEIN DETERMINATION;

EID: 80051669716     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-010-0262-3     Document Type: Article

References (26)

1. Al Mondhiry, H., Ballard, J. O., et al. (1983). Fibrinogen interaction with human platelets: Effect of other coagulation factors, prostaglandins and platelet inhibitors. Thrombosis Research, 31, 415-426.
2. Atherton, H. J., Bailey, N. J., et al. (2006). A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR ± null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiological Genomics, 27, 178-186.
3. Bai, J., Sadrolodabaee, L., et al. (2010). A comparative proteomic analysis of HepG2 cells incubated by S(-) and R(+) enantiomers of anti-coagulating drug warfarin. Proteomics, 10, 1463-1473.
4. Baynes, J., et al. (2005). Medical biochemistry. Philadelphia: Elsevier.
5. Cain, D., Hutson, S. M., et al. (1997). Assembly of the warfarin-sensitive vitamin K 2, 3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. Journal of Biological Chemistry, 272, 29068-29075.
6. Catella, F., Healy, D., et al. (1986). 11-dehydrothromboxane B2: A quantitative index of thromboxane A2 formation in the human circulation. Proceedings of the National Academy of Sciences of the United States of America, 83, 5861-5865.
7. Daviss, B. (2005). Growing pains for metabolomics. Scientist, 19, 25-28.
8. Dunn, W. B., & Ellis, D. I. (2005). Metabolomics: Current analytical platforms and methodologies. TrAC Trends in Analytical Chemistry, 24, 285-294.
9. Halket, J. M., & Zaikin, V. G. (2003). Derivatization in mass spectrometry-1. Silylation. European Journal of Mass Spectrometry, 9, 1-21.
10. Hirsh, J., Dalen, J. E., et al. (2001). Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 119, 8S-21S.
11. Hollander, D., & Rim, E. (1976). Vitamin K2 absorption by rat everted small intestinal sacs. American Journal of Physiology, 231, 415-419.
12. Jansing, R. L., Chao, E. S., et al. (1992). Phase II metabolism of warfarin in primary culture of adult rat hepatocytes. Molecular Pharmacology, 41, 209-215.
13. Kaur-Knudsen, D., Bojesen, S. E., et al. (2009). Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52000 individuals. Pharmacogenomics Journal, 9, 327-332.
14. Kevresan, S., Kuhajda, K., et al. (2006). Biosynthesis of bile acids in mammalian liver. European Journal of Drug Metabolism and Pharmacokinetics, 31, 145-156.
15. Lake, B. G., & Grasso, P. (1996). Comparison of the hepatotoxicity of coumarin in the rat, mouse, and Syrian hamster: A dose and time response study. Fundamental and Applied Toxicology, 34, 105-117.
16. Mainak, M., Koon, K. P., et al. (2009). Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid Communications in Mass Spectrometry, 23, 487-494.
17. Meister, A. (1974). The gamma glutamyl cycle. Diseases associated with specific enzyme deficiencies. Annals of Internal Medicine, 81, 247-253.
18. Miller, G. P., Jones, D. R., et al. (2009). Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chemical Research in Toxicology, 22, 1239-1245.
19. Nassar, A., Talaat, R. E., et al. (2006). The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: Are we all the way there yet? Current Opinion in Drug Discovery & Development, 9, 61-74.
20. Orlowski, M., & Meister, A. (1970). The gamma-glutamyl cycle: A possible transport system for amino acids. Proceedings of the National Academy of Sciences of the United States of America, 67, 1248-1255.
21. Ritter, J. K. (2000). Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chemico-Biological Interactions, 129, 171-193.
22. Tie, J. K., & Stafford, D. W. (2008). Structure and function of vitamin K epoxide reductase. Vitamin K (Vol. 78, pp. 103-130). San Diego: Elsevier Academic Press Inc.
23. Wajih, N., Hutson, S. M., et al. (2007). Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum-a protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K-1 2, 3-epoxide reduction. Journal of Biological Chemistry, 282, 2626-2635.
24. Wharfe, E. S., Winder, C. L., et al. (2010). Monitoring the effects of chiral pharmaceuticals on aquatic microorganisms by metabolic fingerprinting. Applied and Environmental Microbiology, 76, 2075-2085.
25. Wsol, V., Kral, R., et al. (2001). Stereospecificity and stereoselectivity of flobufen metabolic profile in mate rats in vitro and in vivo: Phase I of biotransformation. Chirality, 13, 754-759.
26. Wu, S. M., Cheung, W. F., et al. (1991). Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science, 254, 1634-1636.